Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Ovarian Neoplasms 2Cervical Cancer Metastatic 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Neoadjuvant Therapy 1Melanoma 1Advanced Solid Tumor 1

Interventions

pembrolizumab 141Nivolumab 117Ipilimumab 69Cyclophosphamide 33Specimen Handling 30Magnetic Resonance Spectroscopy 28trametinib 23binimetinib 22fludarabine 21Interleukin-2 21dabrafenib 19relatlimab 17encorafenib 17Biopsy 17aldesleukin 16CTLA-4 Antigen 16cemiplimab 15atezolizumab 15Radiosurgery 15fludarabine phosphate 14Opdualag 14Radiotherapy 11lifileucel 10lenvatinib 10Blood Specimen Collection 10spartalizumab 8Paclitaxel 8Cisplatin 8Bevacizumab 8cobimetinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × famitinib × 1 year × Clear all
NCT07517653 2026-04-08

Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡